Skip to main content
. Author manuscript; available in PMC: 2015 Jan 17.
Published in final edited form as: N Engl J Med. 2014 May 31;371(3):213–223. doi: 10.1056/NEJMoa1400376

Figure 1. Progression-free and Overall Survival.

Figure 1

The durations of progression-free survival (Panel A) and overall survival (Panel B) were significantly longer in the ibrutinib group than in the ofatumumab group. At a median follow-up of 9.4 months, the median duration of progression-free survival was not reached in the ibrutinib group (with a rate of progression-free survival of 88% at 6 months), as compared with a median of 8.1 months in the ofatumumab group; the median duration of overall survival was not reached in either study group.